Attached files
| file | filename |
|---|---|
| EXCEL - IDEA: XBRL DOCUMENT - CORCEPT THERAPEUTICS INC | Financial_Report.xls |
| 10-Q - FORM 10-Q - CORCEPT THERAPEUTICS INC | d588485d10q.htm |
| EX-31.1 - EX-31.1 - CORCEPT THERAPEUTICS INC | d588485dex311.htm |
| EX-31.2 - EX-31.2 - CORCEPT THERAPEUTICS INC | d588485dex312.htm |
| EX-32.2 - EX-32.2 - CORCEPT THERAPEUTICS INC | d588485dex322.htm |
| EX-32.1 - EX-32.1 - CORCEPT THERAPEUTICS INC | d588485dex321.htm |
Exhibit 10.1
Corcept Therapeutics Incorporated
149 Commonwealth Drive
Menlo Park, CA 94025
November 7, 2013
Produits Chimiques Auxiliaires et de Synthese SA (“PCAS”)
23 Rue Bossuet
91161 Longjumeau Cedex
France
Attn. Don LaFerle
| Re: | Extension of Manufacturing and Supply Agreement |
Dear Don,
On behalf of Corcept Therapeutics Inc. (“Corcept”), I propose amending the Manufacturing and Supply Agreement between Corcept and PCAS dated November 3, 2006 (the “Agreement”) as follows:
The language of Section 9.1 (Term) of the Agreement will be deleted in its entirety and replaced with the following text: “This Agreement shall become effective on November 3, 2006 and shall terminate on January 31, 2014.”
Our purpose in proposing this change is to make sure we have an effective contract in place during the next few months while we work the details of a successor agreement.
If this amendment to the Agreement is acceptable to PCAS, please sign and date in the space provided and return a copy to me. Please let me know if you have questions.
Sincerely,
/s/ Charles Robb
Charles Robb
Chief Financial Officer
Corcept Therapeutics Inc.
Approved:
| /s/ Charles Robb | /s/ Donald E. LaFerle | |||
| Signature | Signature | |||
| Chief Financial Officer | Donald E. LaFerle, Sr. Vice President | |||
| Print Name & Title | Print Name & Title | |||
| November 7, 2013 | November 8, 2013 | |||
| Date | Date | |||